Ascendis Pharma (ASND) Misses Q3 EPS by 72c

Ascendis Pharma (NASDAQ: ASND) reported Q3 EPS of (EUR1.00), EUR0.72 worse than the analyst estimate of (EUR0.28). Revenue for the quarter came in at EUR213.63 million versus the consensus estimate of EUR213.17 million.

For earnings history and earnings-related data on Ascendis Pharma (ASND) click here.

You May Also Be Interested In

• Tesla to launch Cybercab in Austin this month - report
• Ionic Digital backs Texas data center audit amid grid reliability push
• Lockheed Martin wins $153 million in defense contracts